GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies | Annals of the Rheumatic Diseases

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

This article has a Reply. Please see:

Response to: ‘The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studies’ by Tillet et al - May 01, 2018

Correspondence

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Tillett W, Orbai A, Ogdie A On Behalf of the GRAPPA OMERACT Psoriatic Arthritis working group, et al

GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies

Annals of the Rheumatic Diseases 2018;77:e23.